204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

Standard 2-year regimens for anti-PD1 agents nivolumab and pembrolizumab may represent excessive treatment because of high target affinity and prolonged PD1 receptor occupation even after discontinuation. Moreover, these agents exhibit a flat dose-response relationship across a wide dose range. Consequently, lower or less frequent doses may retain efficacy whilst reducing toxicity and improving quality-of-life (QOL). Classical, 2-arm non-inferiority designs are inefficient as they only test one reduced dose or prolonged frequency verses control.

Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Ehsan Ghorani, Matteo Quartagno, Fiona Blackhall, Mary O'Brien, Christian Ottensmeier, Elena Pizzo, James Spicer, Duncan Gilbert, Alex Baker, Philip Badman, Charlotte Milner-Watts, Paolo D. d'Arienzo, Adam Dangoor, Jason Adhikaree, Joanne Evans, Pollyanna Tags: Trials in progress Source Type: research